1709956-95-5 Usage
Uses
3-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonyl Chloride is an Impurity of Parecoxib Sodium (P193275), an anti-inflammatory, analgesic.
Clinical Use
Parecoxib is a pro-drug of valdecoxib administered IM or IV for perioperative analgesic and
anti-inflammatory use. As a pro-drug, it undergoes rapid in vivo hydrolysis to valdecoxib.Parecoxib at greater than 20 mg has analgesic activity superior to that of placebo and similar to
that of parenteral 30 or 60 mg of ketorolac in patients with postoperative dental pain. A significant adverse effect is
drug hypersensitivity. Parecoxib is currently marketed worldwide but has not been approved for use in the United
States.
Drug interactions
Potentially hazardous interactions with other drugs
ACE inhibitors and angiotensin-II antagonists:
antagonism of hypotensive effect; increased risk of
nephrotoxicity and hyperkalaemia.
Analgesics: avoid concomitant use of 2 or more
NSAIDs, including aspirin (increased side effects);
avoid with ketorolac (increased risk of side effects
and haemorrhage).
Antibacterials: possible increased risk of convulsions
with quinolones.
Anticoagulants: effects of coumarins and
phenindione enhanced; possibly increased risk of
bleeding with heparin, dabigatran and edoxaban.
Antidepressants: increased risk of bleeding with
SSRIs and venlafaxine.
Antidiabetics: possibly enhanced effect of
sulphonylureas.
Antiepileptics: possibly enhanced effect of phenytoin.
Antifungals: if used with fluconazole reduce the dose
of parecoxib.
Antivirals: increased risk of haematological toxicity
with zidovudine; concentration possibly increased by
ritonavir.
Ciclosporin: potential for increased risk of
nephrotoxicity.
Cytotoxics: reduced excretion of methotrexate,
(possible increased risk of toxicity); increased risk of
bleeding with erlotinib.
Diuretics: increased risk of nephrotoxicity; possible
antagonism of diuretic effect; increased risk of
hyperkalaemia with potassium-sparing diuretics.
Lithium: reduced excretion of lithium (risk of
toxicity).
Pentoxifylline: possibly increased risk of bleeding.
Tacrolimus: increased risk of nephrotoxicity.
Metabolism
Parecoxib is rapidly and almost completely converted to
valdecoxib and propionic acid. Elimination of valdecoxib
is by extensive hepatic metabolism involving multiple
pathways, including cytochrome P 450 (CYP) 3A4 and
CYP2C9 isoenzymes and glucuronidation (about 20%) of
the sulphonamide moiety.
Excretion is mainly via the urine with about 70% of a dose
appearing as inactive metabolites. No unchanged parecoxib is
found in the urine with only trace amounts in the faeces.
Check Digit Verification of cas no
The CAS Registry Mumber 1709956-95-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,7,0,9,9,5 and 6 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1709956-95:
(9*1)+(8*7)+(7*0)+(6*9)+(5*9)+(4*5)+(3*6)+(2*9)+(1*5)=225
225 % 10 = 5
So 1709956-95-5 is a valid CAS Registry Number.
1709956-95-5Relevant articles and documents
A synthesis method of handkerchief auspicious past cloth sodium impurities
-
Paragraph 0007; 0022; 0029; 0033; 0037, (2017/07/01)
The invention discloses a synthetic method of a parecoxib sodium impurity, namely N-[[3-(5-methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]propanamide, belonging to the technical field of chemical pharmacy; the parecoxib sodium impurity is obtained by carryi
METHOD FOR THE PREPARATION OF DIARYLISOXAZOLE SULFONAMIDE COMPOUNDS AND INTERMEDIATES
-
Page/Page column 37-38, (2008/06/13)
The disclosure provides a method for the preparation of a diarylisoxazolé sulfonamide compound comprising contacting a deoxybenzoin with a secondary amine to form a diarylenamine compound; contacting the diarylenamine compound with an acetylating agent to form an acetyl diarylenamine compound; contacting the acetyl diarylenamine compound with a source of hydroxylamine to form an diaryl isoxazolol compound; eliminating water from the diaryl isoxazolol compound to form a diaryl isoxazole compound, chlorosulfonating the diarylisoxazole compound to form a chlorosulfonyl diaryl isoxazole compound; and contacting the chlorosulfonyl diaryl isoxazole compound with a source of ammonia to form the diarylisoxazole sulfonamide compound.
